ERO1A and neoplasm: To determine whether ERO1A in tumor cells has an impact on host anti-tumor immunity and response to immunotherapy, three ERO1A-null (Ero1aKO) cell lines, including MC-38, LLC, and B16 tumors, were introduced using CRISPR-Cas9-based genetic ablation of the Ero1a (Figure 1A).